Table 2.
Pharmacological treatment of COVID-19 patients and differences between patients with or without Candida spp. isolation.
| Treatment regimens | Candida spp.- positive group (n = 31) | Candida spp.-negative group (n = 120) | p-value | Relative Risk (RR) |
|---|---|---|---|---|
| Antibiotics prescription | ||||
| Azithromycin; n (%) | 28 (90.3) | 112 (93.3) | 0.565 | |
| Cephalosporine; n (%) | 30 (96.7) | 118 (98.3) | ||
| Fluoroquinolone; n (%) | 5 (16.1) | 30 (25) | ||
| Carbapenems; n (%) | 3 (9.6) | 10 (8.3) | ||
| Aminoglycosides; n (%) | 2 (6.5) | 7 (5.8) | ||
| Vancomicine; n (%) | 1 (3.2) | 5 (4.2) | ||
| Others; n (%) | 0 | 20 (16.7) | ||
| Hydroxychloroquine; n (%) | 31 (100) | 118 (98.3) | 0.469 | |
| Lopinavir-Ritonavir; n (%) | 18 (58.1) | 34 (28.3) | 0.002 | 1.709, IC95% (1.11–2.62) |
| Tocilizumab; n (%) | 16 (51.6) | 40 (33.3) | 0.05 | 1.378, IC95% (0.94–2.03) |
| Total dose (mg) | 546 | 544 | ||
| Corticosteroids; n (%) | 27 (87.1) | 108 (90) | 0.640 | 1.033 |
| Starting dose (mg) | 140 | 123 | ||
| Treatment regimen; n (%) | ||||
| Regimen 1 | 2 (11.7) | 43 (17) | ||
| Regimen 2 | 10 (58.8) | 113 (45) | 0.138 | |
| Regimen 3 | 5 (29.4) | 96 (38) | ||
| Cyclosporine; n (%) | 5 (16.1) | 11 (9.2) | 0.262 | 1.083 |
| Interferon type 1β; n (%) | 9 (32.1) | 1 (6.2) | 0.049 | 1.382, IC95% (0.81–62.5) |
| Combined IS treatment: | 54,8% | 36% | ||
| TCZ + SC | 12 (38.7) | 43 (28.7) | 0.010 | |
| TCZ + CP | 0 | 0 | ||
| SC + CP | 0 | 7 (4.7) | ||
| TCZ + SC + CZ | 5 (16.1) | 10 (6.7) |
Corticosteroid treatment: Guideline 1 Boluses of 125 mg of methylprednisolone (MTP); Guideline Boluses of 125 mg of MTP, followed by a guideline of 0.5–1 mg/kg/ideal weight for 10 days: Guideline 3 MTP 0.5–1 mg/kg/ideal weight for 10 days. IS: Immunosuppressants TCZ: Tocilizumab SC: Systemic corticosteroids CP: Cyclosporine.